Optimization of 7,12‑dimethylbenz(a)anthracene‑induced rat epithelial ovarian tumors

Yang,Xiu Ying; Li,Ying; Cai,Song Qi; Wang,Li; Qiang,Jin Wei

doi:10.3892/ol.2021.12467

Optimization of 7,12‑dimethylbenz(a)anthracene‑induced rat epithelial ovarian tumors

Authors:
- Xiu Ying Yang
- Ying Li
- Song Qi Cai
- Li Wang
- Jin Wei Qiang
View Affiliations

Affiliations: Department of Radiology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Departments of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of Pathology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: January 14, 2021 https://doi.org/10.3892/ol.2021.12467
Article Number: 206
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian carcinoma is the second most common malignant tumor of the female reproductive system and an notable cause of cancer death. The detection and diagnosis of early ovarian carcinomas are still clinical challenges, which calls for imaging studies using early ovarian carcinoma animal models. The present study aimed to optimize the 7,12‑dimethylbenz(a)anthracene (DMBA)‑induced model of rat ovarian tumors by investigating the delivery methods, induction dose and time of DMBA exposure, and explored the morphological features of tumors using MRI. Three schemes were performed. In scheme one the ovary was covered with absorbable hemostatic gauze loaded with a high concentration of liquid DMBA. For this scheme, 150 Sprague‑Dawley rats were divided into three groups depending on the DMBA dose (1.0, 2.0 and 3.0 mg). In scheme two DMBA solution was injected under the ovarian capsule. For this scheme, 159 rats were divided into 0.5, 1.0 and 1.5 mg DMBA groups. In scheme three the ovary was covered with absorbable gauze loaded with a high concentration of solid DMBA. For this scheme 161 rats were divided into 1.0, 2.0 and 3.0 mg DMBA groups. Each group of the three schemes was further subdivided into 60‑, 90‑, 120‑, 150‑ and 180‑day groups. In scheme two, the tumor formation rate was 75.6% (99/131), which was the highest in the 1.5 mg group (86.4%, 38/44) and reached 100% (10/10) on day 120. The induced tumors were serous in 93.9% (93/99) of tumors. Borderline ovarian tumors accounted for 19.2% (19/99) of all tumors, and ovarian cancer accounted for 46.5% (46/99). The mean maximum diameter (MMD) of borderline ovarian tumors was 10.29±3.41 mm, and that of ovarian cancer was 15.19±7.10 mm. MMD of the solid components increased with increasing malignancy. Cystic, cystic‑solid and solid tumors were observed. The ovarian subcapsular injection of 1.5 mg DMBA was the best scheme for the rat ovarian tumor model. The present model is ideal for investigating the occurrence, development and imaging of ovarian tumors.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clini. 68:394–424. 2018. View Article : Google Scholar
2	Kurman RJ, Carcangiu ML, Herrington CS and Yong RH: WHO Classification of Tumours of Female Reproductive Organs. 6. 4th edition. Lyon: IARC Press, Lyon; pp. pp3072014
3	Prat J: Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 460:237–249. 2012. View Article : Google Scholar : PubMed/NCBI
4	Malpica A, Deavers MT, Tornos C, Kurman RJ, Soslow R, Seidman JD, Munsell MF, Gaertner E, Frishberg D and Silva EG: Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 31:1168–1174. 2007. View Article : Google Scholar : PubMed/NCBI
5	Shih IeM and Kurman RJ: Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 164:1511–1518. 2004. View Article : Google Scholar : PubMed/NCBI
6	Marinaş MC, Mogoş G, Ciurea R and Mogoş DG: EGFR, HER2/neu and Ki67 immunoexpression in serous ovarian tumors. Rom J Morphol Embryol. 53:563–567. 2012.PubMed/NCBI
7	Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, et al: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumors. J Pathol. 202:336–340. 2004. View Article : Google Scholar : PubMed/NCBI
8	Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ and Shih IeM: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 29:218–224. 2005. View Article : Google Scholar : PubMed/NCBI
9	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
10	Irodi A, Rye T, Herbert K, Churchman M, Bartos C, Mackean M, Nussey F, Herrington CS, Gourley C and Hollis RL: Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. BJOG. 127:1409–1420. 2020. View Article : Google Scholar : PubMed/NCBI
11	Stewart C, Ralyea C and Lockwood S: Ovarian cancer: An integrated review. Semin Oncol Nurs. 35:151–156. 2019. View Article : Google Scholar : PubMed/NCBI
12	Stakleff KD and Von Gruenigen VE: Rodent models for ovarian cancer research. Int J Gynecol Cancer. 13:405–412. 2003. View Article : Google Scholar : PubMed/NCBI
13	Hoyer PB, Davis JR, Bedrnicek JB, Marion SL, Christian PJ, Barton JK and Brewer MA: Ovarian neoplasm development by 7,12-dimethylbenz(a)anthracene (DMBA) in a chemically-induced rat model of ovarian failure. Gynecol Oncol. 112:610–615. 2009. View Article : Google Scholar : PubMed/NCBI
14	Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, et al: Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res. 64:8177–8183. 2004. View Article : Google Scholar : PubMed/NCBI
15	Krarup T: Oocyte destruction and ovarian tumorgenesis after direct application of a chemical carcinogen (9:10-dimethyl-1:2-benzanthrene) to the mouse ovary. Int J Cancer. 4:61–75. 1969. View Article : Google Scholar : PubMed/NCBI
16	Kuwahara I: Experimental induction of ovarian tumors in mice treated with single administration of 7,12-dimethylbenz(a)anthracene, and its histopathological observation. Gan. 58:253–266. 1967.PubMed/NCBI
17	Huang Y, Jiang W, Wang Y, Zheng Y, Cong Q and Xu C: Enhanced efficacy and specificity of epithelial ovarian carcinogenesis by embedding a DMBA-coated cloth strip in the ovary of rat. J Ovarian Res. 5:212012. View Article : Google Scholar : PubMed/NCBI
18	Cai SQ, Li Y, Li YA, Wang L, Zhu J, Zhao SH, Li X and Qiang JW: A rat model of serous borderline ovarian tumors induced by 7,12-dimethylbenz(a)anthracene. Exp Anim. 68:257–265. 2019. View Article : Google Scholar : PubMed/NCBI
19	Tanaka YO, Okada S, Satoh T, Matsumoto K, Oki A, Saida T, Yoshikawa H and Minami M: Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: A detailed analysis. Cancer Imaging. 16:32016. View Article : Google Scholar : PubMed/NCBI
20	Xue M, Ji X, Liang H, Liu Y, Wang B, Sun L and Li W: The effect of fucoidan on intestinal flora and intestinal barrier function in rats with breast cancer. Food Funct. 9:1214–1223. 2018. View Article : Google Scholar : PubMed/NCBI
21	Nishida T, Sugiyama T, Kataoka A, Ushijima K and Yakushiji M: Histologic characterization of rat ovarian carcinoma induced by intraovarian insertion of a 7,12-dimethylbenz(a)anthracene-coated suture: Common epithelial tumors of the ovary in rats? Cancer. 83:965–970. 1998. View Article : Google Scholar : PubMed/NCBI
22	Rosenkrantz AB, Sigmund EE, Winnick A, Niver BE, Spieler B, Morgan GR and Hajdu CH: Assessment of hepatocellular carcinoma using apparent diffusion coefficient and diffusion kurtosis indices: Preliminary experience in fresh liver explants. Magn Reson Imaging. 30:1534–1540. 2012. View Article : Google Scholar : PubMed/NCBI
23	Mori N, Ota H, Mugikura S, Takasawa C, Ishida T, Watanabe G, Tada H, Watanabe M, Takase K and Takahashi S: Luminal-type breast cancer: Correlation of apparent diffusion coefficients with the Ki-67 labeling index. Radiology. 274:66–73. 2015. View Article : Google Scholar : PubMed/NCBI
24	Seidman JD and Mehrotra A: Benign ovarian serous tumors: A re-evaluation and proposed reclassification of serous ‘cystadenomas’ and ‘cystadenofibromas’. Gynecol Oncol. 96:395–401. 2005. View Article : Google Scholar : PubMed/NCBI
25	Li YA, Qiang JW, Ma FH, Li HM and Zhao SH: MRI features and score for differentiating borderline from malignant epithelial ovarian tumors. Eur J Radiol. 98:136–142. 2018. View Article : Google Scholar : PubMed/NCBI
26	Chui MH, Xing D, Zeppernick F, Wang ZQ, Hannibal CG, Frederiksen K, Kjaer SK, Cope L, Kurman RJ, Shih IM, et al: Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinoma. Am J Surg Pathol. 43:1462–1472. 2019. View Article : Google Scholar : PubMed/NCBI
27	Zhao SH, Qiang JW, Zhang GF, Boyko OB, Wang SJ, Cai SQ and Wang L: MRI appearances of ovarian serous borderline tumor: Pathological correlation. J Magn Reson Imaging. 40:151–156. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhao SH, Qiang JW, Zhang GF, Wang SJ, Qiu HY and Wang L: MRI in differentiating ovarian borderline from benign mucinous cystadenoma: Pathological correlation. J Magn Reson Imaging. 39:162–166. 2014. View Article : Google Scholar : PubMed/NCBI
29	Tanaka T, Kohno H, Tanino M and Yanaida Y: Inhibitory effects of estrogenic compounds, 4-nonylphenol and genistein, on 7,12-dimethylbenz(a)anthracene-induced ovarian carcinogenesis in rats. Ecotoxicol Environ Saf. 52:38–45. 2002. View Article : Google Scholar : PubMed/NCBI
30	Tanaka T, Kohno H, Suzuki R and Sugie S: Lack of modifying effects of an estrogenic compound atrazine on 7,12-dimethylbenz(a)anthracene-induced ovarian carcinogenesis in rats. Cancer Lett. 210:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
31	Liu L, Hu Z, Zhang H, Hou Y, Zhang Z, Zhou G and Li B: Vitamin D postpones the progression of epithelial ovarian cancer induced by 7, 12-dimethylbenz(a)anthracene both in vitro and in vivo. Onco Targets Ther. 9:2365–2375. 2016. View Article : Google Scholar : PubMed/NCBI